Skip to main content
OpenTrials
Completed

NCT Number: NCT01912950

Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair

The purpose of this randomized, controlled, open-label pilot study is to evaluate the safety and efficacy of a novel intense pulsed light (IPL) device for removal of unwanted fine body hair.

Subjects will have IPL treatment on one forearm area. Another area will serve as the un-treated control area. Subjects will be followed at 12-weeks post-final treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sadick Research Group

New York, 10075, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female or Male, 18 to 65 years of age (inclusive).
  • Fitzpatrick Skin Type I - III.
  • Subject has black or dark brown unwanted arm hair of fine texture.
  • Willing to have the hair removal procedure on one forearm only, and within the designated study treatment area.
  • Willing and able to adhere to the treatment and follow-up schedule, and the study "Before and After Procedure Instructions".
  • Willing to refrain from shaving the treatment area for 5 days prior to each study visit.
  • Must be able to read, understand and sign the Informed Consent Form.
  • Must agree not to use hair removal products, such as topical chemical depilatories, or undergo any other hair removal procedure during the study, such as other laser and light therapies or waxing.
  • Willing to refrain from excess sun exposure and willing to wear sunscreen on the treatment area during the study (including the follow-up period).
  • Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
  • Must be in good health, as determined by the Investigator.
  • Must be post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.

Exclusion criteria

  • Participation in a clinical trial of another device or drug within 6 months prior to enrollment, or during the study.
  • Had any type of professional hair removal procedure, such as laser, light-based, RF or electrolysis, in the treatment area within 12 months of study participation.
  • Had other epilation treatment, such as waxing or mechanical epilator, in the treatment area within 6 months of study participation.
  • Subject shows signs of actinic bronzing or recent tanning in the treatment area, and unable/unlikely to refrain from tanning during the study.
  • Subject is pregnant and/or breastfeeding.
  • Suffering from significant concurrent illness, such as diabetes mellitus or pertinent neurological disorders.
  • Having malignant or pre-malignant lesions in the treatment area, or history of a malignant skin disease.
  • Current acute or chronic skin infections or inflammatory processes, affecting the treatment area, such as dermatitis.
  • Currently using immunosuppressive medications or history of immunosuppression/immune deficiency disorder, such as psoriasis, eczema, vitiligo, systemic lupus erythematosus or scleroderma.
  • Current use of any medication that is known to increase sensitivity to light, such as tetracycline.
  • Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment within 3 months of study participation.
  • Suffering from coagulation disorders or taking prescription anticoagulation medications.
  • History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing.
  • History of seizure disorders due to light.
  • History of diseases stimulated by heat, such as recurrent herpes zoster in the treatment area, unless treatment is conducted following a prophylactic regimen.
  • History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
  • History of tattoo, permanent make-up or semi-permanent or permanent tissue fillers in the treatment area.
  • Systemic use of a retinoid (such as Accutane) or corticosteroid within 6 months of study participation.
  • Current smoker or history of smoking within 12 months of study participation.
  • Anytime in life, had used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Treatment and study plan

Prowave LX IPL

Device

Other names: Prowave, Prowave LX, Cutera Prowave LX, Intense Pulsed Light, IPL, Flashlamp Infared device, Hair removal

Primary outcomes

  1. Comparison of Percent Hair Reduction Between Treatment Arm and Non-treated Control Arm at 12 Weeks Post Final Treatment

    Time frame: 12-weeks

Sponsors and collaborators

Lead sponsor

Cutera Inc.

Industry

Registry information

Official study title

Randomized, Controlled, Open-Label Pilot Study of a Novel IPL for Removal of Unwanted Fine Hair

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jul 31, 2013
Registry last updated
Feb 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.